New York, February 13, 2026, 10:29 (EST) — Regular session
- Erasca added 1.1%, trading at $12.44 as of Friday morning.
- Keep an eye on ERAS-0015 and ERAS-4001 for possible news as Guggenheim’s biotech summit unfolds.
- Coming up: the Feb. 26 fireside chat at Oppenheimer’s healthcare conference.
Erasca Inc shares edged 1.1% higher to $12.44 Friday morning, after touching a session high of $12.65 earlier on.
Investors pored over details from Thursday’s Guggenheim Emerging Outlook: Biotech Summit, where Erasca’s update became a focal point. The company highlighted ERAS-0015, a “molecular glue” designed to break up RAS signaling, alongside ERAS-4001, a KRAS inhibitor aimed at a wide range of targets. RAS remains a tough cancer culprit, and these “pan” approaches are built to hit multiple mutations at once. ERAS-0015’s dose reached up to 40 mg, according to the summary. Phase 1 data for ERAS-0015 is expected in the first half of 2026, with ERAS-4001 results slated for later that year. Quartr
Cash remains top of mind for early-stage biotech investors, despite recent market gains. Erasca, in a Jan. 29 filing, said it finished 2025 holding about $341.8 million in cash, cash equivalents and marketable securities. The company also highlighted $242.7 million in preliminary, unaudited net proceeds from a January stock offering. That pile should keep operations running into the first half of 2029, Erasca said.
At one stage Thursday, the stock jumped 6.8%, according to MarketBeat, even as trading volume stayed below normal levels.
Erasca said in January that ERAS-0015 delivered both confirmed and unconfirmed partial responses across several tumor types during dose escalation. No dose-limiting toxicities turned up at the doses they tested. CEO Jonathan Lim called the early low-dose responses “thesis-reinforcing.” Erasca
Erasca’s been shoring up cash while pushing its RAS pipeline forward. On Jan. 23, the company closed an upsized public offering, unloading 25.875 million shares at $10 apiece. Gross proceeds landed around $258.8 million.
The investor-conference scene this week has been tense, with the RAS-pathway drug rivalry intensifying as multiple players step onto the same stage. Revolution Medicines entered the fray at the Guggenheim biotech summit on Feb. 11, staking its claim among the competition.
On Erasca, traders want numbers: which tumors are involved, how long those responses stick, and whether pushing the dose higher makes tumors shrink faster—without stirring up new side effects. Dose-limiting toxicity is the sticking point here, the adverse event that blocks companies from cranking up the dose another level.
Early tumor shrinkage might fade, and new side effects could crop up when trials expand or dosages increase. On top of that, with so many competitors crowding the field, a faster or more straightforward update from a different company can quickly squeeze the smaller names.
Erasca is set to make another appearance—this time at Oppenheimer’s Healthcare Life Sciences Conference, slated for Feb. 26, the company said. Investors want sharper timelines for the Phase 1 update, plus specifics on any combo approaches.
